The diagnostic value of 14-3-3η protein levels in patients with rheumatoid arthritis. Issue 4 (August 2018)

• Record Type: Journal Article
• Authors: Shovman, O.; Gilburd, B.; Watad, A.; Amital, H.; Langevitz, P.; Bragazzi, N.L.; Adawi, M.; Perez, D.; Bornstein, G.; Grossman, C.; Lidar, M.; Blank, M.; Azuri, J.; Biln, N.K.; Marotta, A.; Shoenfeld, Y.
• Is Part Of: Best practice & research. Volume 32:Issue 4(2018:Aug.)
• Page Start: 610
• Page End: 617
• Publication Date: 2018-08
• Subjects: Rheumatoid arthritis -- Biomarkers -- 14-3-3η -- Autoantibodies -- Autoimmunity; Rheumatology -- Periodicals; Rheumatic Diseases -- Periodicals; Reumatologie; 616.723005
• DOI: 10.1016/j.berh.2019.01.010
• Languages: English
• ISSNs: 1521-6942

Abstract

Abstract: 14-3-3η may represent a useful diagnostic biomarker for rheumatoid arthritis (RA). We assessed the prevalence and serum levels of 14-3-3η in patients with RA and in patients with other rheumatic diseases. Serum levels of 14-3-3η were measured in 96 patients with RA, in 101 patients with other rheumatic diseases, and in 66 healthy subjects. All of the sera samples were evaluated by JOINT stat 14-3-3η ELISA test kits (Augurex Life Sciences Corp.). Median (IQR) 14-3-3η levels were significantly higher in the early RA group [0.25 ng/ml (0.075–3.11)] and in patients with established RA [0.15 ng/ml (0.08–1.26)] than in healthy subjects [0 ng/ml (0-0)] and disease controls: SLE [0.01 ng/ml (0–0.055)], AS [0.05 ng/ml (0–0.255)], and PsA [0.01 ng/ml (0–0.065)]. The prevalence of 14-3-3η positivity in patients with early RA was 58%, significantly higher than that in disease controls and healthy subjects (p < 0.001). In patients with established RA, this prevalence was 43%, and it was significantly higher than that in patients with other rheumatic diseases and healthy subjects (p < 0.05), excluding the AS group (p = 0.054). In the early RA cohort, the positivity for 14-3-3η, RF, and anti-CCP was 58%, 67%, and 71%, respectively. Eighty-two percent of the patients in this cohort were positive for at least one of these biomarkers. The concentration of 14-3-3η protein may be used to distinguish between patients with early RA and patients with other rheumatic diseases.